The main of this study is to assess the feasibility of a patients follow-up visit receiving trastuzumab subcutaneous by Advanced Practice Nurse.

Inclusion Criteria:

• Patient care at the Cancer Institute Lucien Neuwirth
• Patient aged over 18 years
• Patient with breast cancer overexpressing HER2 adjuvant
• Patient having finished their chemotherapy treatment with IV followed the oncologist day hospital
• Patient under Trastzumab subcutaneously
• Patient affiliated or entitled to a social security scheme (mandatory requirement for all studies)

Exclusion Criteria:

• Refusal to participate, most patient protected under guardianship.
• Patient in inability to understand the course of the study
• Patient with documented history of cognitive or psychiatric disorders.
• Patients pregnant or lactating
• Patients under guardianship or curatorship